Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07727889) titled 'A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa' on July 22.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Peking Union Medical College

Condition: Hidradenitis Suppurativa (Acne Inversa)

Intervention: Drug: Upadacitinib

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: July 1, 2026

Target Sample Size: 50

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT077278...